SCHEMBL30738282

SCHEMBL30738282

COC(=O)c1cc(Br)c(F)cc1C(Br)Br

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SOS1 Q07889 1/20 0.44
LMNA P02545 2/20 0.38
TSHR P16473 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
NR4A2 P43354 1/20 0.37
NOTUM Q6P988 2/20 0.36
SIRT6 Q8N6T7 1/20 0.35
CA12 O43570 2/20 0.34
CA1 P00915 2/20 0.34
CA2 P00918 2/20 0.34
CA7 P43166 2/20 0.34
CA9 Q16790 2/20 0.34
CA14 Q9ULX7 2/20 0.34
PDK2 Q15119 1/20 0.34
PDK4 Q16654 1/20 0.34
KDM4E B2RXH2 4/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
GAA P10253 2/20 0.33
SLC6A3 Q01959 2/20 0.33
POLB P06746 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21585802 1.00 SOS1 (0.44) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL29165250 0.94 SOS1 (0.41) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL16637297 0.87 SOS1 (0.44) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL31394743 0.83 SOS1 (0.51) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL31739075 0.83 SOS1 (0.40) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL365953 0.81 SOS1 (0.50) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL31079873 0.81 SOS1 (0.50) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL31254604 0.81 SOS1 (0.41) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL24803082 0.79 SOS1 (0.40) SOS1LMNATSHRNPSR1NR4A2
SCHEMBL20571340 0.78 SOS1 (0.48) SOS1LMNATSHRNPSR1NR4A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112204028-B tetrahydro-1H-pyrazino [2,1-a ] isoindoloquinoline compounds for use in the treatment of autoimmune diseases 豪夫迈·罗氏有限公司 2023-12-29 CN disclosed